Diabetic Macular Edema (DME) Completed Phase 4 Trials for Aflibercept (DB08885)

Also known as: Diabetic Macular Edema(DME) / Diabetic Macular Oedema / Macular Edema, Diabetic / Diabetic Macular Edema / Macular edema due to diabetes mellitus (disorder) / Diabetic retinal oedema / Diabetic retinal edema

IndicationStatusPhase
DBCOND0060562 (Diabetic Macular Edema (DME))Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02633852Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular EdemaTreatment
NCT04411693Comparative Study of Dexamethasone Implant to Intravitreal Aflibercept in Subjects With Diabetic Macular EdemaTreatment
NCT03780361Changes in Inflammatory Biomarkers Including Soluble CD14 and Hyperreflective Foci in DME Patients Treated With Aflibercept (FORESIGHT)Basic Science
NCT05511038A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular EdemaTreatment
NCT03984110One Year Trial Evaluating Safety of Ozurdex With EyleaTreatment
NCT04087746Comparison of Aflibercept Versus Ranibizumab in Management of Diabetic Macular Edema (DME)Treatment
NCT03866746Aflibercept With and Without Micropulse Laser in Diabetic Macular EdemaTreatment
NCT03453281Early Anatomical, Physiological, and Clinical Changes in Diabetic Macular Edema After Intravitreal Aflibercept InjectionTreatment
NCT03340610IAI for Persistent DME After Treatment With Bevacizumab And RanibizumabTreatment
NCT02503540Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVOTreatment
NCT02471651Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular EdemaTreatment
NCT02441907Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Diabetic Macular EdemaTreatment
NCT02392364Variable Interval Versus Set Interval Aflibercept for DMETreatment
NCT02299336Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME TrialTreatment
NCT02297204The Endurance 1 TrialPrevention